Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2011.467 | PROACTYVE pilot: Pilot study of Patient | Prof Yeo Winnie |
| 2010.422 | A Phase II trial of BAY 86-9766 plus sorafenib as a first line systemic treatment for hepatocellular carcinoma (HCC) | Prof. Yeo Winnie |
| 2013.427 | A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in patients with RAS mutant Hepatocellular Carcinoma(HCC) | Prof Yeo Winnie |
| 2009.444 | A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC) | Prof. Yeo Winnie |
| 2006.340 | Predictors of Survival in Patients with Unresectable Hepatocellular Carcinoma-Clinical, Quality of Life and Virological Factors | Prof. YEO Winnie |
| 2012.472 | A Two-Cohort, Open-Label, Multicenter, Study of Trastuzumab Emtansine (T-DM1) in HER2 Positive Locally Advanced or Metastatic Breast Cancer Patients who have Received Prior Anti-HER2 and Chemotherapy-Based Treatment | Prof. YEO Winnie |
| 2010.201 | An Open-label, Randomized Phase 3 Study of Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC) | Prof. Yeo Winnie |
| 2013.088 | A Phase 1/2, Dose-escalation, Open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Advanced Hepatocellular Carcinoma Subjects with or without Chronic Viral Hepatitis; and a Randomized, Open-label Study of Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma Subjects who are Naive to Systemic Therapy | Prof. YEO Winnie |
| 2009.158 | Effect of Genetic Polymorphisms and Gene Expression in Chemotherapy-Related Toxicities in Chinese Breast Cancer Patients | Prof Yeo Winnie |
| 2011.196 | Quality of life of Chinese patients with hepatocellular carcinoma and its value as prognosticator for the disease | Prof Yeo Winnie |
| 2009.077 | Clinical Application of Genetic Markers in Prediction of Doxorubicin and Taxane Induced Cytotoxicity in Mammary Cancer Patients of Asian Ethnicity | Prof Yeo Winnie |
| 2008.090 | Identification of Tumor Suppressor Function and Prognostic Role of Deleted in Lung and Esophageal Cancer 1 (DLEC1) Gene in Hepatocellular Carcinoma | Prof. YEO Winnie |
| 2013.417 | GASTRIC CANCER PATIENTS RECEIVING ADJUVANT TS-1- A SURVEY ON PATIENTS’ TOLERABILITY | Prof. YEO Winnie |
| 2012.158 | Design Innovation and Customisation of the Mastectomy Bra and Prosthesis for Hong Kong Mastectomy Patients: A Multidisciplinary Approach | Prof. YEO Winnie |
| 1995.526 | Randomized Trial of High-Dose Epirubicin and Cyclophamide x 3 Supported by Peripheral Blood Projector Cells Versus Anthracycline and Cyclophosphamide x 4 Followed by Cyclophosphamide, Methotrexate & 5- Fluorouracil as Adjuvant Treatment for High Risk Operable Stage II and Stage III Breast Cancer in Premenopausal and Young Postmenopausal (<65 yrs) Patients | Prof. YEO Winnie |
| 2014.078 | The prognostic significance of combination of AFP, DCP and AFP L3 as biomarkers in hepatocellular carcinoma | Prof. YEO Winnie |
| 2010.204 | Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B treated with anti-B cell therapy-Effective and Cost-Effectiveness of prevention | Prof. Yeo Winnie |
| 2010.326 | A longitudinal study of psychosocial needs and psychological distress of Chinese women with advanced breast cancer: A follow-up study | Prof. YEO Winnie |
| 2018.392 | A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (KEYNOTE-859) |
Prof. YEO Winnie 楊明明 |
| 2018.363 | A RETROSPECTIVE STUDY ON EFFICACY AND TOLERABILITY OF COMBINATION FLOT CHEMOTHERAPY AS NEOADJUVANT CHEMOTHERAPY IN GASTRIC CANCER PATIENTS |
Prof. YEO Winnie 楊明明 |
| 2019.476 | A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER |
Prof. YEO Winnie 楊明明 教授 |
| 2018.528 | A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER |
Prof. YEO Winnie 楊明明 教授 |
| 2018.435 | A Phase 3, multicenter, randomized, open-label, active-controlled study of Trastuzumab Deruxtecan (DS-8201A), an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane (DESTINY-Breast03) |
Prof. YEO Winnie 楊明明 |
| 2020.258 | A Phase 2, Single Arm, Multi-center, Open-Label Trial to Evaluate the Safety and Efficacy of Treatment with Tumor Treating Fields (TTFields) and Chemotherapy as First-Line Treatment for Subjects with Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Gastric (GC) Adenocarcinoma. |
Prof. YEO Winnie 楊明明 |
| 2019.551 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT, HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER |
Prof. YEO Winnie 楊明明 教授 |
| 2020.653 | A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015) |
Prof. YEO Winnie 楊明明教授 |
| 2020.330 | Scalp Cooling Study for the Prevention of Chemotherapy-induced Alopecia in Chinese Breast Cancer Patients |
Prof. YEO Winnie 楊明明教授 |
| 2024.342 | A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | Prof. YEO Winnie |
| 2024.409 | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy | Prof. YEO Winnie |
| 2023.240 | Surgical accuracy and clinical outcomes of image-free versus image-based robotic-assisted total knee arthroplasty | Dr. YEE King Hang |
| 2020.505 | Sterilized 3D PRINTed bone models versus conventional CT imaging for operative visualization for complex fracture repair surgery – A randomized multicentre study |
Dr. YEE King Hang 余敬行醫生 |
| 2020.659 | Determinants of osteoarthritis outcomes and progression in persons with late-stage knee osteoarthritis over 18 months | Dr. YEE Dennis King Hang |
| 2022.146 | Reliability and validity of pre-excision gap balancing assessment in robotic total knee replacement |
Dr. YEE Dennis King Hang 余敬行 |
| 2023.215 | Evaluation of the Effectiveness of Irreversible Electroporation for the Treatment of Prostate Cancer |
Dr. YEE Chi Hang 余知行 |
| 2017.394 | A Comprehensive Evaluation of the Transgender Population in Hong Kong: An Age-Matched, and Sex- or Preferred Gender-Matched Comparative Observational Study. |
Dr. YEE Chi Hang 余知行 |
| 2015.613 | The Associations between Severity Level of Lower Urinary Tract Symptoms and Cardiovascular Risk in Male Patients in Hong Kong |
Dr. YEE Chi Hang 余知行 |
| 2016.248 | Prevention of Lymphocele with Floseal in Renal Transplantation: A Multicentre Randomized Controlled Trial |
Dr. YEE Chi Hang 余知行 |
| 2016.588 | A Telephone Survey of Lower Urinary Tract Symptoms and Health in Hong Kong |
Dr. YEE Chi Hang 余知行 |
| 2020.019 | Robotic Radical Perineal Prostatectomy for Localized Prostate Cancer: A Feasibility Study |
Dr. YEE Chi Hang 余知行 |
| 2019.535 | Music as an Adjunct for Pain and Anxiety Relief during Urological Procedure: A Randomized Control Trial |
Dr. YEE Chi Hang 余知行 |
| 2020.018 | Evaluation of the Effectiveness of Cryotherapy for the Treatment of Prostate Cancer |
Dr. YEE Chi Hang 余知行 |
| 2019.043 | Image-guided robot-assisted waterjet ablation of the prostate for patients with retention of urine due to benign prostatic obstruction |
Dr. YEE Chi Hang 余知行 |
| 2018.556 | Evaluation of the Effectiveness of High-intensity Focused Ultrasound for the Treatment of Prostate Cancer |
Dr. YEE Chi Hang 余知行 |
| 2024.091 | Using social norms to promote physical activity among physically inactive college students in China: A randomized controlled trial |
Mr. YE Xinchen 叶欣晨 |
| 2014.255 | A cross-sectional study of cardio-metabolic risk in Chinese women with Polycystic Ovary Syndrome | Dr Yau Tse Ling |
| 2013.462 | A study of operational model efficiency: the improvement on service equality and efficiency in the delivery process of home based rehabilitation service (HBRS), by developing a new route planning system and a new discharge logistic plan, for the poor and | Mr. Yau Ngok |
| 2014.072 | Retrospective study of Use of Levetiracetam in Neonates | Dr. Yau Lo Yee |
| 2024.009 | Phenotypic landscape and genotype correlations in patients with SCN1A mutation | Dr Yau Lo Yee |
| 2022.105 | Neuro-modulation in patients with refractory epilepsy – a multicenter study in Hong Kong SAR, China |
Dr. YAU Lo Yee 邱露儀 |
| 2019.501 | Patients’ barriers to use Non-vitamin K novel oral anticoagulants in high risk nonvalvular atrial fibrillation patients in General Outpatient Clinic in Hong Kong |
Dr. YAU King Sun 游景新 |
Page 14 of 253.